The FDA granted Eagle Pharmaceuticals approval to market its orphan drug Ryanodex (dantrolene sodium) as a treatment for malignant hyperthermia (MH), an inherited and potentially fatal disorder triggered by certain anesthesia agents in genetically susceptible people.
Shares of Eagle climbed up 4.8%, or 63 cents, on 23 July. But the stock closed down 46 cents at...





